The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
Abstract
Background S100A12 is a member of the damage-associated molecular pattern molecules (DAMP) and expressed by activated granulocytes exhibiting its proinflammatory capacity by binding to the Receptor for Advanced Glycation Endproducts (RAGE). The aim of this study was to evaluate S100A12 in MWS patients before and during therapy with Anakinra (IL1Ra) and Canakinumab (a fully human monoclonal antibody against...
Paper Details
Title
The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
Published Date
Sep 1, 2008
Journal
Volume
6
Issue
S1
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History